BioSpace News Archive

Decibel Therapeutics , a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that their clinical product candidate, DB-020, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). DB-020 is an investigational therapy for the prevention of cisplatin-induced hearing loss, a serious and debi

Positive and negative coronavirus swabs and associated de-identified medical data can accelerate researchers’ work on treatments and vaccines

The U.S. Food and Drug Administration (FDA) has approved Benlysta to treat lupus nephritis (lupus-related kidney disease) in adults. The approval is for both the intravenous and subcutaneous formulations. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disea

Essence Group , a leading global IoT solutions provider, today announced it will showcase two advanced 5G-connected IoT devices at the upcoming CES that demonstrate the company’s position at th

Regulatory News Transgene (Paris:TNG) today announced its financial reporting dates for 2021: March 10, 2021: 2020 Fiscal Year Results April 27, 2021: First Quarter 2021 Financial Results May 26, 2021: Annual Shareholders’ Meeting

The Lupus Research Alliance (LRA) congratulates GSK on the U.S. Food and Drug Administration (FDA) approval of belimumab (Benlysta ® ) as the first-ever treatment indicated specifically for adults with lupus nephritis (LN), a complication of systemic lupus erythematosus (SLE). Another milestone, this new indication is the only FDA appro

Today Stand Up To Cancer® (SU2C) unveiled a collaborative initiative aimed at improving colorectal cancer screening, early detection and prevention across the United States.

Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc, an innovative drug development company, today announced that they have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis’ CDNF and xCDNF therapies (Parkinson’s disease) using Nanofor

Dr. Irfan Khan, CEO and Founder of Circuit Clinical, and Dr. Gene D Morse, Director of the Center for Integrated Global Biomedical Sciences (CIGBS), University at Buffalo, The State University of New York (SUNY), announce a collaboration to conduct regional, national, and international clinical research for prevention and treatment of SARS-CoV-2.

Kiromic BioPharma (“the Company”) (NASDAQ: KRBP) , a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology, announced today the submission of two investigational new drug (IND) applications with the U.S. Food and Drug Administration (FDA) for the initiation of: --- Phase 1 clinical trial of an intravenously (IV) ad